Dihexa: missing human data and retracted foundational studies

What is dihexa?

Dihexa is a synthetic compound derived from angiotensin IV. It was designed for oral use and to cross the blood-brain barrier. Academic researchers studied it as a possible candidate for cognitive disorders. In the market for so-called research chemicals, it is sold for brain function and memory. It is not an approved medicine.

How is dihexa supposed to work?

Dihexa is intended to promote new connections between nerve cells by enhancing signaling through hepatocyte growth factor, HGF, and its receptor, c-Met. The key paper describing this mechanism has been retracted, however, weakening the preclinical rationale itself. The remaining supporting data come from cell experiments and rodent studies. They do not establish a clinical benefit in humans.

Is dihexa FDA-approved?

According to the source text, dihexa is not approved by the FDA or any other authority. The source also states that it is absent from the relevant FDA compounding lists and was not among the peptides evaluated at the FDA’s 2026 advisory meetings on compounding.

What does the research show?

The evidence is preclinical, and the reliability of part of it has been called into question. Animal experiments have been reported, including maze-based memory tests 1. The foundational mechanism paper, however, was retracted 2. Completed human efficacy trials are lacking. There is therefore no reliable evidence that dihexa improves human cognitive performance.

Frequently asked questions

Is dihexa approved in the US?

At the September 2026 cutoff specified in the source text, dihexa is not FDA-approved for any human use. The source also states that compounding under section 503A is not permitted. The FDA removed the substance from Category 2 in April 2026 4, but it is on neither the 503A list of eligible bulk substances nor Category 1. The source text concludes that there is no regular prescription route in the US.

Is dihexa legal in the US?

According to the source text, dihexa is not approved for human use. It is sold through gray-market channels labeled “for research use only.” That label does not automatically make human use lawful. Its precise legal classification as a consumer product requires expert regulatory review.

Can a doctor prescribe dihexa?

The source text states that a lawful, patient-specific compounded prescription under section 503A is not available because dihexa is on neither the FDA’s relevant 503A bulk-substance list nor Category 1. It therefore says that a licensed pharmacy cannot prepare it for an individual prescription. According to the source, offers of such prescriptions fall outside the established regulatory framework.

Where does the claim that dihexa is “10 million times more potent than BDNF” come from?

This comparison does not appear in the two central published dihexa papers. They described dihexa inducing new synapse formation in rat hippocampal neurons at picomolar concentrations 5. The paper linking this effect to HGF/c-Met has since been retracted. High potency at one endpoint in a cell experiment says nothing reliable about cognitive effects in humans. BDNF’s varied receptor and signaling effects also cannot meaningfully be reduced to a simple concentration comparison.

Have important dihexa papers been retracted?

Yes. A 2012 paper describing molecules in this class as mimics of HGF dimerization was formally retracted in April 2025 6. An editorial Expression of Concern had already appeared in 2021. A 2014 paper in the same journal attributed the cognitive and synapse-forming effects of angiotensin IV-derived peptides to HGF/c-Met. It too was retracted in April 2025 7, following a corresponding notice in 2021. The 2013 paper on improved cognitive function in rats after oral administration has also carried an Expression of Concern since 2021 8, but, according to the source text, has not been formally retracted. Both the biochemical foundations and the central mechanistic explanation have therefore been publicly questioned.

Is dihexa safe?

At the September 2026 cutoff specified in the source text, no human safety data are available. The source also states that no data on human exposure to dihexa products were found 4. It reports no published phase 1 dose-escalation trial, pharmacokinetic profile or systematic collection of adverse effects. The proposed c-Met agonist mechanism also raises a theoretical cancer-risk question: c-Met signaling is associated with tumor growth, invasion and metastasis in several cancers 9. Whether, and how, that translates into a risk from dihexa has not been studied.

Are there human efficacy data?

No. According to the source text, published data on cognitive effects come exclusively from rodent models. It states that no human efficacy or safety trial has been completed and, as of September 2026, no trial was registered on ClinicalTrials.gov 10. An independent laboratory confirmed some of the preclinical findings in mice 11. Whether they translate to humans remains open.

How does dihexa differ from other nootropic peptides?

Dihexa is a small peptidomimetic derived from angiotensin IV. In rodents, oral bioavailability and passage across the blood-brain barrier are proposed. This distinguishes it from many experimental peptides that are injected. Its proposed HGF/c-Met mechanism also differs from approaches involving growth hormone secretagogue receptors, BDNF signaling or the acetylcholine system. The key considerations are that the findings are entirely preclinical, foundational papers have been retracted, human data are missing and a theoretical cancer-risk question remains unresolved.

Further reference literature

General reference literature on therapeutic peptides: Journal of the AAOS Global Research & Reviews, 2025, Reference 3.

References cited in the source text

Sources: general reference literature on therapeutic peptides noting the absence of clinical trials for dihexa (Journal of the AAOS Global Research & Reviews, 2025, DOI: 10.5435/JAAOSGlobal-D-25-00236 3), indexed on PubMed; the retraction of the primary dihexa mechanism paper is noted in the PubMed record.

Provenance and editorial review status

Adapted for Nutrient Desk from the source article. The claims and source attributions in the original text still require clinical review. This draft has not been cleared for indexing.